TX-MAVENIR
12.4.2022 09:02:15 CEST | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announced the collaboration with Aspire Technology (Aspire), a specialized Network Solutions developer and System Integrator, to accelerate the market availability of O-RAN split 7.2 compliant Remote Radiohead Units (RRUs) leveraging Aspire’s Open Networks Lab in Europe.
Communication Service Providers (CSPs) demand for integrated high performing Open Radio Access Network (Open RAN) solutions based on Mavenir O-RAN compliant cloud-native Centralized Unit (CU) and Distributed Unit (DU) RAN software stacks is growing fast, fueled by modernization and coverage expansion projects, as well as private networks and indoor projects.
The number of O-RAN compliant RRUs from partners globally is also growing with sophisticated products across the different radio technologies, including Massive MIMO (mMIMO) and millimeter Wave (mmWave).
Mavenir and Aspire will be leveraging Aspire’s Open Networks Lab in Dublin for third-party RRU integration and testing. Furthermore, RRU vendors will be able to engage directly with Aspire and fast-track the integration and testing of new O-RAN compliant radios and frequency variants with Mavenir CU/DU software.
This collaboration will benefit not only RRU vendors, but also CSPs by expanding the offering of innovative and high-performing solutions supporting a wide number of use cases.
“This partnership greatly enhances the capacity to integrate and test RRUs with Mavenir’s CU/CU for 4G and 5G,” said Puneet Sethi, SVP/GM RAN Business for Mavenir. “Open RAN has accelerated to a point that we need to continuously innovate to be ahead of demand, including go-to-market models. Our RRU partners want to get their newest products available for deployment, and CSPs want to take full advantage of a fast-paced ecosystem minimizing integration and testing effort. We are continuously expanding our partner eco-systems for RRU integration to respond to the evolving market needs with specialized high-quality services and fast turnaround.”
Declan Friel, CTO, Aspire said; “We are delighted to extend our relationship with Mavenir. Aspire’s heritage in software engineering and testing of complex radio products carried over into Open RAN, combined with global CSP experience through design, optimization and support of live networks, uniquely positions us to accelerate the availability of new ORAN compliant solutions for wide market adoption. As a European-based independent company, and with our Open Networks Lab in Ireland today supporting a number of global clients and partners, our focus has been to accelerate the ORAN ecosystem development and to support CSPs. This will allow them to fully realize the benefits of Telco Cloud, Service Management & Orchestration and Open RAN, in terms of flexibility, performance and cost.”
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
About Aspire:
Aspire Technology is a leading Specialized System Integrator with a long history and experience in fixed and mobile networks, and Open RAN since its early days. Aspire’s clients are spread around the Globe and benefit from their advanced services and software automation solutions. The Aspire Open RAN Lab enables technology partners and communications service providers to fasttrack development, integration, benchmarking, testing and deployment of Open RAN based networks and solutions. Aspire has been actively contributing to acceleration of time to market, reduction of deployment cost and improvement of multivendor interoperability and network performance. www.aspiretechnology.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220412005063/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom